This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Frank Andrew to its Clinical Business Development team.
Frank joins PCI as a Business Development Manager, with responsibility for supporting clients in the Asia-Pacific region to ensure continued growth and success in this expanding market. Frank has an extensive background in business development within the pharmaceutical sector with varying roles at international businesses spanning more than 35 years.
The appointment of a new business development role for Clinical trial supply services in the Asia-Pacific region comes on the heels of the recent announcement of PCI’s acquisition of leading provider Pharmaceutical Packaging Professionals (PPP), based in Melbourne, Australia. The site will be PCI’s regional headquarters for activity in the Australia and greater Asia-Pacific region, expanding PCI’s presence in the area with manufacturing, packaging and labeling, as well as logistical services for investigational studies. PPP recently embarked on a significant facilities expansion to support growing demand for its services, particularly in the area of sterile drug manufacture. PPP features extensive capability to service early phase clinical study and has further expanded to support business growth in later stage studies as its clients progress their pipeline candidates towards commercialization. PPP provides investigational medicines to an extensive list of countries in the Asia-Pacific region, complementing PCI’s existing logistical supply in the area.
Frank will report to Paul Viggers, Director of Clinical Business Development. He joins PCI from another leading outsourced clinical services provider, where he worked as a Senior Global Account Manager.
Commenting on the appointment, Paul said: “Frank brings a great deal of valuable experience in business development from his significant career in the industry. I know he will become a key asset to our existing and prospective clients across the Asia-Pac region, supporting them from molecule to market, and ensuring successful outcomes for the development of their lifesaving medicines.”
Frank said of his new role: “I’m delighted to join PCI and apply my previous experience to my new position. I have a long history of providing insights to clients in support of making their studies more efficient and effective. I hope this will prove valuable for PCI’s clients in helping them realize their goals in pharmaceutical development.”
In addition to the PPP acquisition and retention of Frank Andrew in a key business development role, PCI has been actively investing in its core business and has recently announced key site capacity expansions as well as site investments in Cold Chain infrastructure. PCI announced Cold Chain and Ultra Cold Chain expansions at its Philadelphia and Rockford locations in support of temperature-controlled packaging, storage and distribution. Furthermore, PCI has also embarked on site expansions of its manufacturing center of excellence in Tredegar, UK and clinical trial center of excellence in Bridgend, UK as they experience growing demand.
For more information, click here